


PHARMACEUTICAL 2022

MUSTANG BIO INC. Rank 313 of 475





PHARMACEUTICAL 2022

MUSTANG BIO INC. Rank 313 of 475

The relative strengths and weaknesses of MUSTANG BIO INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MUSTANG BIO INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 98% points. The greatest weakness of MUSTANG BIO INC. is the variable Research and Development, reducing the Economic Capital Ratio by 185% points.

The company's Economic Capital Ratio, given in the ranking table, is -211%, being 65% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	111,706
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,815
Liabilities, Non-Current	1,685
Other Assets	13,464
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	270
Other Net Income	353
Property and Equipment	0
Research and Development	55,706
Revenues	0
Selling, General and Administrative Expense	11,017

Output Variable	Value in 1000 USD
Assets	125,170
Liabilities	12,770
Expenses	66,723
Stockholders Equity	112,400
Net Income	-66,370
Comprehensive Net Income	-66,370
Economic Capital Ratio	-211%